Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Purple Biotech American Depositary Shares Representing 200 Ord Shs PPBT

Healthcare
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi... see more

Recent & Breaking News (NDAQ:PPBT)

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

GlobeNewswire 1 day ago

Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer

GlobeNewswire 2 days ago

Purple Biotech Reports Third Quarter 2024 Financial Results

GlobeNewswire November 15, 2024

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

GlobeNewswire November 4, 2024

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

GlobeNewswire October 25, 2024

Purple Biotech to Present Data for its Tri-Specific Antibody Platform-CAPTN-3-at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

GlobeNewswire October 10, 2024

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

GlobeNewswire September 18, 2024

Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research

GlobeNewswire September 10, 2024

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire August 30, 2024

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire August 16, 2024

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

GlobeNewswire July 25, 2024

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

GlobeNewswire July 10, 2024

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

GlobeNewswire July 2, 2024

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

GlobeNewswire July 1, 2024

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

GlobeNewswire June 27, 2024

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

GlobeNewswire June 1, 2024

Purple Biotech Reports First Quarter 2024 Financial Results

GlobeNewswire May 21, 2024

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

GlobeNewswire April 25, 2024

Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024

GlobeNewswire March 28, 2024

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

GlobeNewswire March 14, 2024